

Fabio M Iwamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7850065/publications.pdf>

Version: 2024-02-01

42
papers

3,183
citations

279798

23
h-index

315739

38
g-index

48
all docs

48
docs citations

48
times ranked

4753
citing authors

#	ARTICLE	IF	CITATIONS
1	Causes of Death and End-of-Life Care in Patients With Intracranial High-Grade Gliomas. <i>Neurology</i> , 2022, 98, .	1.1	6
2	Diagnosis of Leptomeningeal Metastasis in Women With Breast Cancer Through Identification of Tumor Cells in Cerebrospinal Fluid Using the CNSideâ„¢ Assay. <i>Clinical Breast Cancer</i> , 2022, 22, e457-e462.	2.4	6
3	Axicabtagene CiloleuceL in Patients Ineligible for ZUMA-1 Because of CNS Involvement and/or HIV: A Multicenter Experience. <i>Journal of Immunotherapy</i> , 2022, 45, 254-262.	2.4	6
4	ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. <i>Nature Cancer</i> , 2021, 2, 1372-1386.	13.2	39
5	Surgery plus adjuvant radiotherapy for primary central nervous system lymphoma. <i>British Journal of Neurosurgery</i> , 2020, 34, 690-696.	0.8	10
6	Can patient selection and neoadjuvant administration resuscitate PD-1 inhibitors for glioblastoma?. <i>Journal of Neurosurgery</i> , 2020, 132, 1667-1672.	1.6	10
7	CTNI-25. PHASE IB CLINICAL TRIAL OF CHRONIC CONVECTION-ENHANCED DELIVERY OF TOPOTECAN FOR RECURRENT GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii47-ii48.	1.2	0
8	Immunotherapy Against Gliomas: is the Breakthrough Near?. <i>Drugs</i> , 2019, 79, 1839-1848.	10.9	10
9	Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma. <i>Nature Medicine</i> , 2019, 25, 462-469.	30.7	569
10	Craniotomy and Survival for Primary Central Nervous System Lymphoma. <i>Neurosurgery</i> , 2019, 84, 935-944.	1.1	46
11	Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma. <i>Journal of Neuro-Oncology</i> , 2018, 137, 303-311.	2.9	43
12	INNV-06. FACTORS INFLUENCING RECEPTIVITY TO CLINICAL RESEARCH IN AN URBAN NEURO-ONCOLOGY PRACTICE. <i>Neuro-Oncology</i> , 2018, 20, vi139-vi139.	1.2	0
13	QOLP-05. THE EFFECT OF RESILIENCE ON QUALITY OF LIFE IN PATIENTS WITH HIGH GRADE GLIOMAS AND THEIR CAREGIVERS. <i>Neuro-Oncology</i> , 2018, 20, vi215-vi215.	1.2	0
14	First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. <i>Journal of Translational Medicine</i> , 2018, 16, 142.	4.4	376
15	The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis. <i>Journal of Neuro-Oncology</i> , 2017, 132, 189-197.	2.9	25
16	Rindopemimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	10.7	776
17	Go, no-go decision making for phase 3 clinical trials: ACT IV revisited â€œ Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e709-e710.	10.7	5
18	ATIM-07. STUDY OF PEMBROLIZUMAB, TUMOR TREATMENT FIELDS (OPTUNEÂ®) AND TEMOZOLOMIDE FOR OLDER SUBJECTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2017, 19, vi27-vi27.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Primary Central Nervous System Lymphoma: A Critical Review of the Role of Surgery for Resection. Archives in Cancer Research, 2016, 4, .	0.3	18
20	RTHP-37. RATES AND IMPACT OF COMPLIANCE WITH TUMOR TREATING FIELDS THERAPY IN AÂGLIOMA COHORT. Neuro-Oncology, 2016, 18, vi182-vi182.	1.2	0
21	ATIM-34. RATES AND OUTCOMES OF COMBINATION TUMOR TREATING FIELDS AND IMMUNOTHERAPY IN AÂGLIOMA COHORT. Neuro-Oncology, 2016, 18, vi25-vi25.	1.2	2
22	Frailty in Geriatric Glioblastoma Patients: A Predictor of Operative Morbidity and Outcome. World Neurosurgery, 2016, 89, 362-367.	1.3	98
23	Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma. Practical Radiation Oncology, 2016, 6, 306-314.	2.1	17
24	The genetic landscape of dural marginal zone lymphomas. Oncotarget, 2016, 7, 43052-43061.	1.8	28
25	Factorial clinical trials: a new approach to phase II neuro-oncology studies. Neuro-Oncology, 2015, 17, 174-176.	1.2	6
26	The Safety of Surgery in Elderly Patients with Primary and Recurrent Glioblastoma. World Neurosurgery, 2015, 84, 913-919.	1.3	44
27	MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System. PLoS ONE, 2014, 9, e114398.	2.5	38
28	Unveiling YKL-40, from Serum Marker to Target Therapy in Glioblastoma. Frontiers in Oncology, 2014, 4, 90.	2.8	25
29	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro-Oncology, 2014, 16, 1541-1546.	1.2	12
30	Primary Central Nervous System Tumors in the Aging Population. Current Translational Geriatrics and Experimental Gerontology Reports, 2013, 2, 182-187.	0.7	0
31	Age-Specific Signatures of Glioblastoma at the Genomic, Genetic, and Epigenetic Levels. PLoS ONE, 2013, 8, e62982.	2.5	49
32	Recursive partitioning analysis of prognostic factors for glioblastoma patients aged 70 years or older. Cancer, 2012, 118, 5595-5600.	4.1	95
33	Radiotherapy and concomitant temozolomide may improve survival of elderly patients with glioblastoma. Journal of Neuro-Oncology, 2012, 109, 391-397.	2.9	58
34	Atypical and anaplastic meningiomas treated with bevacizumab. Journal of Neuro-Oncology, 2012, 109, 187-193.	2.9	155
35	Primary Brain Tumors in the Elderly. Current Neurology and Neuroscience Reports, 2010, 10, 252-258.	4.2	23
36	Glioblastoma in the elderly. Cancer, 2009, 115, 3758-3766.	4.1	103

#	ARTICLE	IF	CITATIONS
37	Prognosis and patterns of care in elderly patients with glioma. <i>Cancer</i> , 2009, 115, 5534-5540.	4.1	51
38	A phase II trial of vinorelbine and intensive temozolomide for patients with recurrent or progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2008, 87, 85-90.	2.9	40
39	Clinical relevance of 1p and 19q deletion for patients with WHO grade 2 and 3 gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 293-298.	2.9	49
40	Patterns of care in elderly glioblastoma patients. <i>Annals of Neurology</i> , 2008, 64, 628-634.	5.3	177
41	An Update on Primary Central Nervous System Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 1267-1285.	2.2	21
42	Primary dural lymphomas: a review. <i>Neurosurgical Focus</i> , 2006, 21, 1-5.	2.3	96